Benicar (olmesartan): Ongoing Safety Review

Audience: Cardiology, Internal Medicine [UPDATED 04/14/2011] After reviewing the results of the ROADMAP and ORIENT trials, FDA has determined that the benefits of Benicar continue to outweigh its potential risks when used for the treatment of…

Related posts:

1. Revlimid (lenalidomide): Ongoing Safety Review – Increased Risk of Developing New Malignancies Audience: Hematology, Oncology ISSUE: FDA is informing the public that...
2. Abacavir – Ongoing Safety Review: Possible Increased Risk of Heart Attack Audience: Infectious Disease including Ziagen, Trizivir, and Epzicom ISSUE: FDA...